Abstract
Clozapine is primarily used in patients with treatment‐refractory schizophrenia. Its pharmacokinetic profile reflects variable bioavailability, ranging from 27 to 70%, and complex metabolic pathways, with CYP1A2 as the primary drug‐metabolizing enzyme as well as additional involvement by others (CYP2C19, CYP2D6, and CYP3A4). In addition, enzymatic activity of CYP1A2 is increased by smoking, which is common in patients with schizophrenia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
